Aptose Biosciences Received its Third Buy in a Row

By Jason Carr

After Canaccord Genuity and Roth Capital assigned a Buy rating to Aptose Biosciences in the last month, the company received another Buy, this time from H.C. Wainwright. Analyst Joseph Pantginis reiterated a Buy rating on Aptose Biosciences (NASDAQ: APTO) today and set a price target of $6. The company’s shares opened today at $3.41.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -13.8% and a 32.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Aptose Biosciences is Strong Buy and the average price target is $6.33, representing an 85.6% upside.

In a report released today, Roth Capital also reiterated a Buy rating on the stock with a $6 price target.

Based on Aptose Biosciences’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $0 and GAAP net loss of $3.29 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $3.29 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product portfolio includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG’806.